Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Paul E. Oberstein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5918-6004; OpenAlex author ID A5015984085. Sources: ClinicalTrials.gov.

Their work

Papers
32 (first author 3, last author 3)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
191
Papers, trials and grants by year

2005: 1 trial · 2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 4 papers · 2025: 6 papers · 2026: 5 papers

Papers 32

  1. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Co-author DOI 10.1038/s41591-026-04283-z↗
  2. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  3. Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag091↗
  4. Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More. First author DOI 10.1158/1078-0432.ccr-25-4177↗
  5. Correction: Chang et al. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Cancers 2025, 17, 630. Co-author DOI 10.3390/cancers18050789↗
  6. Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2025.3377↗
  7. Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions. First author DOI 10.1007/s11864-025-01352-2↗
  8. A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery. Co-author DOI 10.1093/oncolo/oyaf162↗
  9. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Co-author DOI 10.1093/oncolo/oyaf271↗
  10. Association of tumor microbiome with survival in resected early-stage PDAC. Co-author DOI 10.1128/msystems.01229-24↗
  11. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Co-author DOI 10.3390/cancers17040630↗
  12. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Last author DOI 10.1093/oncolo/oyae210↗
  13. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  14. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  15. Somatic Mutational Analysis in Endoscopic Ultrasound-Guided Biopsy of Pancreatic Adenocarcinoma: Assessing Yield and Impact. Co-author DOI 10.14309/ajg.0000000000002786↗
  16. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Co-author DOI 10.1038/s41467-023-36296-4↗
  17. Author Correction: Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Co-author DOI 10.1038/s41467-023-39680-2↗
  18. Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.33500↗
  19. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… Co-author DOI 10.1158/1078-0432.ccr-21-0929↗
  20. The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials. Last author DOI 10.1097/jp9.0000000000000052↗
  21. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  22. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elast… Co-author DOI 10.7150/thno.37965↗
  23. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Co-author DOI 10.1136/gutjnl-2018-317706↗
  24. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  25. Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma Co-author DOI 10.1101/288779↗
  26. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancrea… Co-author DOI 10.1200/jco.2017.74.9564↗
  27. Current and Emerging Therapies in Metastatic Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-16-2319↗
  28. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.17237↗
  29. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ccr.2014.04.021↗
  30. Pancreatic cancer: why is it so hard to treat? Co-author DOI 10.1177/1756283x13478680↗
  31. Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study. Co-author DOI 10.3109/07357907.2013.789904↗
  32. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22,… Co-author PMID 21386629↗

Trials 2

  1. A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer Principal investigator NCT00882310↗
  2. Capecitabine and Temozolomide for Neuroendocrine Cancers Principal investigator NCT00869050↗

Closest collaborators

The 25 strongest of 191 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gulam Abbas Manji · 5 shared papers, 2017–2026 · strength 1.03
  2. Andrew Eugene Hendifar · 5 shared papers, 2018–2026 · strength 0.99
  3. Tamas A. Gonda · 5 shared papers, 2023–2026 · strength 0.96
  4. Diane M. Simeone · 5 shared papers, 2021–2024 · strength 0.76
  5. Zev A. Wainberg · 4 shared papers, 2019–2026 · strength 0.68
  6. An Ngo‐Huang · 2 shared papers, 2025–2026 · strength 0.62
  7. Nathan H. Parker · 2 shared papers, 2025–2026 · strength 0.62
  8. Andrew L. Coveler · 2 shared papers, 2025–2026 · strength 0.62
  9. Philip J. Chang · 2 shared papers, 2025–2026 · strength 0.62
  10. Gillian K. Gresham · 2 shared papers, 2025–2026 · strength 0.62
  11. Susan Elaine Bates · 3 shared papers, 2020–2026 · strength 0.56
  12. Chengwei Peng · 1 shared paper, 2025 · strength 0.54
  13. Manuel M. Hidalgo · 2 shared papers, 2021–2026 · strength 0.53
  14. Nathan Bahary · 4 shared papers, 2018–2026 · strength 0.52
  15. John A. Chabot · 5 shared papers, 2013–2025 · strength 0.51
  16. Ruth Aroon White · 2 shared papers, 2025–2026 · strength 0.49
  17. Richard Bernard Hayes · 2 shared papers, 2025 · strength 0.46
  18. Yixuan Meng · 2 shared papers, 2025 · strength 0.46
  19. Jiyoung Ahn · 2 shared papers, 2025 · strength 0.46
  20. Kenneth P. Olive · 6 shared papers, 2013–2020 · strength 0.45
  21. Eileen Mary O'Reilly · 2 shared papers, 2026 · strength 0.44
  22. Shubham Pant · 2 shared papers, 2026 · strength 0.44
  23. Peter Y. Yu · 1 shared paper, 2026 · strength 0.43
  24. Anirban Maitra · 1 shared paper, 2026 · strength 0.43
  25. Gregor Werba · 3 shared papers, 2023–2024 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.